NextCure Provides Update and Reports Third Quarter 2022 Financial Results
November 03, 2022 16:15 ET
|
NextCure
Discontinuing development of our NC318 programAdvancing clinical pipeline: NC410 combination, NC525, and NC762 Extending runway into mid-2025 (an additional 15 months) BELTSVILLE, Md., Nov. 03, 2022...
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
November 03, 2022 09:15 ET
|
NextCure
BELTSVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
October 27, 2022 16:05 ET
|
NextCure
BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
October 05, 2022 08:15 ET
|
NextCure
BELTSVILLE, Md., Oct. 05, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors
October 04, 2022 16:05 ET
|
NextCure
BELTSVILLE, Md., Oct. 04, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure to Present at the Ladenburg Thalmann Healthcare Conference
September 22, 2022 08:00 ET
|
NextCure
BELTSVILLE, Md., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
August 04, 2022 16:05 ET
|
NextCure
On track to report data from all three clinical programsSecond quarter ending cash of $185.5 million expected to fund operations into the first quarter of 2024 BELTSVILLE, Md., Aug. 04, 2022 (GLOBE...
NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation
July 06, 2022 08:00 ET
|
NextCure
BELTSVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM
June 27, 2022 08:00 ET
|
NextCure
BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting
June 22, 2022 08:00 ET
|
NextCure
BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...